Medicare & Medicaid Services (CMS) Center has delayed the implementation of the new application rule for certain skin replacement transplantation by January 1, 2026. The acting decision comes from a continuous review of the guarantee policy to ensure the patient’s access to effective skin replacement products supported by strong evidence.
In light of this expansion, the CMS demanded that the public source of fellow reviews and high -quality evidence were submitted. The deadline for submitting this information is November 1, 2025. Collected evidence is delivered to the Medicare Administrative Contractors (MACS), which will be evaluated for adjustment for LCD (Local Coverage Degency).
Such development can have a significant impact on a company that generates this type of transplant to companies such as MIMEDX (MDXG, Financial) and Orgo (Orgo). Both companies may need to continue to provide strong evidence to support the effect of the product to ensure the consistent guarantee and repayment of Medicare.
Wall Street analysts predicted
Based on the one -year price goal provided by four analysts, the average target price of MIMEDX Group Inc (MDXG, Financial) is $ 13.75, a high estimate is $ 16.00 and a low estimation is $ 12.00. The average goal is the current price of $ 6.73 to 104.31%. More detailed data can be found on the MIMEDX Group Inc (MDXG) prediction page.
According to the agreement recommendation of five brokerage companies, the average brokerage recommendation of MIMEDX Group Inc (MDXG, Financial) is currently 2.0, indicating a “excellent performance” state. The grade scale is from 1 to 5, 1 means a strong purchase and 5 represents sales.
According to the Gurufocus estimates, the estimated GF value of MIMEDX Group Inc (MDXG, Financial) for a year suggests $ 6.82, suggesting an increase of 1.34%from $ 6.73. The GF value is an estimation of Gurufocus for the fair value that stocks must trade. It is calculated based on the historical drainage of the previous stocks as well as the future estimates of past business growth and business performance. More data can be found on the MIMEDX Group Inc (MDXG) summary page.
